Your browser doesn't support javascript.
loading
Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.
Wang, Bin; Liu, Lixiao; Wu, Jinting; Mao, Xiaolu; Fang, Zhen; Chen, Yingyu; Li, Wenfeng.
Afiliación
  • Wang B; Department of Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Liu L; Department of Obstetrics and Gynecology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Wu J; Department of Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Mao X; Department of Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Fang Z; Department of Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Chen Y; Department of Neurosurgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Li W; Department of Medical Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Front Genet ; 13: 711142, 2022.
Article en En | MEDLINE | ID: mdl-35222525
Clear cell renal cell carcinoma (ccRCC) is one of the most aggressive malignancies in humans. Hypoxia-related genes are now recognized as a reflection of poor prognosis in cancer patients with cancer. Meanwhile, immune-related genes play an important role in the occurrence and progression of ccRCC. Nevertheless, reliable prognostic indicators based on hypoxia and immune status have not been well established in ccRCC. The aims of this study were to develop a new gene signature model using bioinformatics and open databases and to validate its prognostic value in ccRCC. The data used for the model structure can be accessed from The Cancer Genome Atlas database. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were used to identify the hypoxia- and immune-related genes associated with prognostic risk, which were used to develop a characteristic model of prognostic risk. Kaplan-Meier and receiver-operating characteristic curve analyses were performed as well as independent prognostic factor analyses and correlation analyses of clinical characteristics in both the training and validation cohorts. In addition, differences in tumor immune cell infiltrates were compared between the high and low risk groups. Overall, 30 hypoxia- and immune-related genes were identified, and five hypoxia- and immune-related genes (EPO, PLAUR, TEK, TGFA, TGFB1) were ultimately selected. Survival analysis showed that the high-risk score on the hypoxia- and immune-related gene signature was significantly associated with adverse survival outcomes. Furthermore, clinical ccRCC samples from our medical center were used to validate the differential expression of the five genes in tumor tissue compared to normal tissue through quantitative real-time polymerase chain reaction (qRT-PCR). However, more clinical trials are needed to confirm these results, and future experimental studies must verify the potential mechanism behind the predictive value of the hypoxia- and immune-related gene signature.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: China